Sanofi And Selecta Target Allergies | Chemical & Engineering News
Volume 90 Issue 49 | p. 19 | Concentrates
Issue Date: December 3, 2012

Sanofi And Selecta Target Allergies

Department: Business
Keywords: allergies, immunotherapy, vaccines

Sanofi and Selecta Biosciences are joining to develop antigen-specific immunotherapies for allergies using Selecta’s synthetic vaccine particle technology. Under the agreement, Sanofi obtains an exclusive license to develop an immunotherapy against a life-threatening food allergen and an option to develop two more allergy therapies. Selecta can receive milestone payments totaling up to $300 million for each of the three drug candidates. Selecta was founded in 2008 by MIT professor Robert Langer and two Harvard Medical School professors.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment